Clovis Oncology (CLVS) Tops Q4 EPS by 6c

Clovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($0.50), $0.06 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $36 million versus the consensus estimate of $39.08 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance